Wakamoto Pharmaceutical Co.,Ltd. (TSE: 4512)
Health Care · Pharmaceuticals · JP
¥297.00
+9.19% today · -3.6% 1Y
Wakamoto Pharmaceutical Co.,Ltd. (TSE: 4512) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $65.00M and employs 303 people.
Over the last twelve months the share price has lost 3.6%, trading between 240.00 and 380.00.
Tweenvest scores Wakamoto Pharmaceutical Co.,Ltd. across four factors: quality 64/100, value 45/100, dividend 23/100. Its strongest factor is quality.
4512 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $65.00M
- Revenue (TTM)
- $114.45M
- P/E
- —
- EPS
- -6.38
- Dividend yield
- 1.01%
- Beta (5Y)
- 0.43
- 52-week high
- ¥380.00
- 52-week low
- ¥240.00
- Avg volume (3M)
- —
- Shares outstanding
- 34.79M
- Employees
- 303
- Next earnings
- —
About Wakamoto Pharmaceutical Co.,Ltd.
Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.
- ISIN
- JP3991200001
- Founded
- 1929
- Listed since
- Jan 1, 2001
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,190.02 | -3.54% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.56 | -0.94% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.39 | -1.96% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.33 | -0.86% |
Figures last refreshed Aug 18, 2026.